Form D · Biotechnology
Excision BioTherapeutics Inc
San Francisco, CA · CIK 0001847173
Offering snapshot reported Mar 3, 2021 · SEC filing
- Reported sold
- $10.5M Offering amount: $10.5M
- Investors reported
- 6 Form D · investor count
- Minimum accepted
- $1 Reported outside-investor minimum
- First sale
- Feb 16, 2021 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Mar 3, 2021 | Initial | $10,500,000 | No comparison | 6 | SEC filing |
| Feb 22, 2021 | Initial | $60,738,974 | No comparison | 32 | SEC filing |
Offering details
- Securities
- Equity, Debt, Other
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-391112
Offering of convertible promissory notes ("Notes") and the underlying shares of equity securities issuable upon conversion of the Notes.
Source: Form D, filed Mar 3, 2021. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Vasudev Bailey | Director |
| William Carson | Director |
| Daniel Dornbusch | Director, Executive |
| Ashok Krishnamurthi | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
988 Market Street, Second Floor
San Francisco, CA, 94102
San Francisco, CA, 94102